Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

摘要: Lung cancer is the most frequently diagnosed and a leading cause of mortality worldwide, with adenocarcinoma being common histological subtype. Deeper understanding pathobiology non-small cell lung (NSCLC) has led to development small molecules that target genetic mutations known play critical roles in progression metastatic disease influence response targeted therapies. The principle goal precision medicine define those patient populations likely respond However, genome landscape composed relatively few “mountains” [representing commonly mutated genes like KRAS, epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK)] vast number “hills” (representing low frequency but potentially actionable mutations). Low-frequency lesions affect druggable gene product allow population patients for therapy be selected.